Assessing Leukemia Patients by Using MRD Testing

02.19.20

Assessing Leukemia Patients by Using MRD Testing

by Kate Jacobson

Biotech Start-Up Adaptive Biotechnologies Looks at Innovative Diagnostic Kits, Including MRD

02.02.20

Biotech Start-Up Adaptive Biotechnologies Looks at Innovative Diagnostic Kits, Including MRD

by Kate Jacobson

Data on Emerging Treatments in Myeloma Unveiled at ASH

01.27.20

Data on Emerging Treatments in Myeloma Unveiled at ASH

by Kate Jacobson

FDA Finalizes 2018 Guidance on Use of Minimal Residual Disease

01.27.20

FDA Finalizes 2018 Guidance on Use of Minimal Residual Disease

by Kate Jacobson

Sagar Lonial, MD, Discusses Role of Anti-BCMA Therapies

01.16.20

Sagar Lonial, MD, Discusses Role of Anti-BCMA Therapies

by Kate Jacobson

Adaptive and Genentech Partner to Use clonoSEQ® Assay to MRD in Study of Chronic Lymphocytic Leukemia Patients

01.16.20

Adaptive and Genentech Partner to Use clonoSEQ® Assay to MRD in Study of Chronic Lymphocytic Leukemia Patients

by Adaptive Biotechnologies

Dr C. Ola Landgren: MRD Is a Growing Topic of Interest in Cancer

01.10.20

Dr C. Ola Landgren: MRD Is a Growing Topic of Interest in Cancer

by Kate Jacobson

$Complete Response, MDR Negativity Linked to Lower Relapse Risk in Relapsed/Refractory AML$

01.03.20

Complete Response, MDR Negativity Linked to Lower Relapse Risk in Relapsed/Refractory AML

by Kate Jacobson

Theme picker